Compare Stocks: LENZ, DRUG, ASMB, and SPRY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$22.54 -1.9%	$29.09	$21.80 ▼ $39.71	$467.89M	1.15	376,115 shs	367,967 shs
DRUG Bright Minds Biosciences	$50.69 +3.0%	$68.91	$48.53 ▼ $123.75	$478.92M	-5.22	92,454 shs	154,688 shs
LENZ LENZ Therapeutics	$3.58 -5.5%	$4.80	$3.51 ▼ $49.85	$119.08M	0.64	710,227 shs	1.13 million shs
SPRY ARS Pharmaceuticals	$4.07 -1.2%	$5.26	$3.98 ▼ $13.15	$409.72M	0.85	1.40 million shs	1.83 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-1.91%	-4.77%	-38.62%	-18.75%	-8.41%
DRUG Bright Minds Biosciences	+3.01%	-2.14%	-28.73%	-25.01%	-12.53%
LENZ LENZ Therapeutics	-5.54%	-8.44%	-38.28%	-39.22%	-92.70%
SPRY ARS Pharmaceuticals	-1.21%	-0.25%	-30.07%	-52.45%	-59.66%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$22.54 -1.9%	$29.09	$21.80 ▼ $39.71	$467.89M	1.15	376,115 shs	367,967 shs
DRUG Bright Minds Biosciences	$50.69 +3.0%	$68.91	$48.53 ▼ $123.75	$478.92M	-5.22	92,454 shs	154,688 shs
LENZ LENZ Therapeutics	$3.58 -5.5%	$4.80	$3.51 ▼ $49.85	$119.08M	0.64	710,227 shs	1.13 million shs
SPRY ARS Pharmaceuticals	$4.07 -1.2%	$5.26	$3.98 ▼ $13.15	$409.72M	0.85	1.40 million shs	1.83 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	-1.91%	-4.77%	-38.62%	-18.75%	-8.41%
DRUG Bright Minds Biosciences	+3.01%	-2.14%	-28.73%	-25.01%	-12.53%
LENZ LENZ Therapeutics	-5.54%	-8.44%	-38.28%	-39.22%	-92.70%
SPRY ARS Pharmaceuticals	-1.21%	-0.25%	-30.07%	-52.45%	-59.66%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	110.74% Upside
DRUG Bright Minds Biosciences	2.90	Moderate Buy	$143.83	183.75% Upside
LENZ LENZ Therapeutics	2.50	Moderate Buy	$28.80	704.47% Upside
SPRY ARS Pharmaceuticals	2.50	Moderate Buy	$25.00	514.25% Upside

Current Analyst Ratings Breakdown

Latest LENZ, DRUG, ASMB, and SPRY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	DRUG Bright Minds Biosciences	Lifesci Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/9/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	SPRY ARS Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$53.00 ➝ $45.00
8/25/2026	LENZ LENZ Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Perform
8/20/2026	DRUG Bright Minds Biosciences	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy

(Data available from 10/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	6.35	N/A	N/A	$13.04 per share	1.73
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
LENZ LENZ Therapeutics	$19.09M	5.89	N/A	N/A	$9.09 per share	0.39
SPRY ARS Pharmaceuticals	$84.28M	4.80	N/A	N/A	$1.16 per share	3.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	22.10	450.80	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	12/22/2026 (Estimated)
LENZ LENZ Therapeutics	-$82.13M	-$4.09	N/A	N/A	N/A	-586.74%	-53.39%	-49.14%	11/4/2026 (Estimated)
SPRY ARS Pharmaceuticals	-$171.30M	-$2.18	N/A	N/A	N/A	-184.24%	-256.67%	-69.63%	11/9/2026 (Estimated)

Latest LENZ, DRUG, ASMB, and SPRY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
8/13/2026	Q2 2026	SPRY ARS Pharmaceuticals	-$0.4777	-$0.63	-$0.1523	-$0.63	$31.32 million	$33.66 million
8/11/2026	Q2 2026	LENZ LENZ Therapeutics	-$1.05	-$1.02	+$0.03	-$1.02	$2.38 million	$5.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
SPRY ARS Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
DRUG Bright Minds Biosciences	N/A	122.00	122.00
LENZ LENZ Therapeutics	N/A	13.55	13.31
SPRY ARS Pharmaceuticals	13.72	3.48	3.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
DRUG Bright Minds Biosciences	40.52%
LENZ LENZ Therapeutics	54.32%
SPRY ARS Pharmaceuticals	68.16%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
DRUG Bright Minds Biosciences	42.66%
LENZ LENZ Therapeutics	8.30%
SPRY ARS Pharmaceuticals	33.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Not Optionable
LENZ LENZ Therapeutics	152	31.42 million	28.81 million	N/A
SPRY ARS Pharmaceuticals	200	99.45 million	65.83 million	Optionable

LENZ, DRUG, ASMB, and SPRY Headlines

Recent News About These Companies

ARS Pharmaceuticals Officer Eric Karas Files Form 144 to Sell 100,000 Shares on NASDAQ

October 2 at 7:54 PM | kalkinemedia.comK

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

October 2 at 6:01 PM | prnewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

October 2 at 2:57 PM | globenewswire.com

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role

October 2 at 2:43 PM | globenewswire.com

Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (SPRY) Lead Plaintiff Deadline is October 5, 2026

October 1 at 4:30 PM | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm

October 1 at 12:00 PM | globenewswire.com

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

October 1 at 10:26 AM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY

October 1 at 10:00 AM | prnewswire.com

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

October 1 at 9:53 AM | prnewswire.com

Critical Survey: ARS Pharmaceuticals (NASDAQ:SPRY) and Nutriband (NASDAQ:NTRB)

October 1 at 6:15 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Now Rated "Moderate Buy" by Sell-Side Analysts

October 1 at 6:14 AM | americanbankingnews.com

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Has Consensus Price Target of $25.00

October 1 at 6:13 AM | marketbeat.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 30 at 3:51 PM | newsfilecorp.comN

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

September 30 at 12:51 PM | prnewswire.com

ARS Pharmaceuticals, Inc. (SPRY)

September 30 at 8:51 AM | finance.yahoo.com

Bank of America Corp DE Makes New Investment in ARS Pharmaceuticals, Inc. $SPRY

September 30 at 3:19 AM | marketbeat.com

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

September 29, 2026 | newsfilecorp.comN

Kaplan Fox Notifies Investors: Deadline to Lead in the ARS Pharmaceuticals Inc. (SPRY) Securities Class Action is October 5, 2026

September 29, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY

September 29, 2026 | globenewswire.com

SueWallSt Reminds ARS Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - SPRY

September 29, 2026 | globenewswire.com

ARS PHARMACEUTICALS DEADLINE: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY

September 29, 2026 | newsfilecorp.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LENZ, DRUG, ASMB, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$22.54 -0.44 (-1.91%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$22.76 +0.23 (+1.00%)

As of 10/2/2026 07:30 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Bright Minds Biosciences NASDAQ:DRUG

$50.69 +1.48 (+3.01%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$52.01 +1.32 (+2.61%)

As of 10/2/2026 08:00 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

LENZ Therapeutics NASDAQ:LENZ

$3.58 -0.21 (-5.54%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.66 +0.09 (+2.37%)

As of 10/2/2026 07:30 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

ARS Pharmaceuticals NASDAQ:SPRY

$4.07 -0.05 (-1.21%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.07 (+1.72%)

As of 10/2/2026 07:44 PM Eastern

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, DRUG, ASMB, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, DRUG, ASMB, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, DRUG, ASMB, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LENZ, DRUG, ASMB, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Bright Minds Biosciences NASDAQ:DRUG

LENZ Therapeutics NASDAQ:LENZ

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LENZ, DRUG, ASMB, and SPRY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LENZ, DRUG, ASMB, and SPRY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LENZ, DRUG, ASMB, and SPRY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LENZ, DRUG, ASMB, and SPRY Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Bright Minds Biosciences NASDAQ:DRUG

LENZ Therapeutics NASDAQ:LENZ

ARS Pharmaceuticals NASDAQ:SPRY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools